Sarcoidosis Clinical Trial
Official title:
Test-retest Reliability for Fatigue Assessment Scale, Short Form 6 Dimension and King's Sarcoidosis Questionnaire
Verified date | August 2020 |
Source | University of East Anglia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study aims to see if people's health related quality of life (how they feel about their health) changes over a 12 week period if they do not receive any change in their medicines. The investigators would like people to complete four questionnaires then repeat them after three months. The investigators need to do this to in order see what difference they should expect to detect if they give people treatment that works.
Status | Active, not recruiting |
Enrollment | 20 |
Est. completion date | November 1, 2020 |
Est. primary completion date | May 10, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or Female aged over 18 - Diagnosed with sarcoidosis by either; biopsy confirming non-caseating granulomas consistent with sarcoidosis, or multi-disciplinary interstitial lung disease meeting diagnosis of sarcoidosis - Significant fatigue - defined as a FAS score of greater than 21 points - Has mental capacity to complete the questionnaires Exclusion Criteria: - Presence of another significant cardio-respiratory disease, major organ disease (except where related to sarcoidosis) or chronic inflammatory condition |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Norwich Medical School | Norwich | Norfolk |
Lead Sponsor | Collaborator |
---|---|
University of East Anglia | Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK) |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fatigue Assessment Scale (FAS) | Fatigue Assessment Scale (FAS) - ranges from 10 to 50 with higher values representing greater fatigue. There are a specified cut-off values for clinically significant fatigue (score >= 22) and severe fatigue (score >= 35).The questionaire was administered at baseline, 6 weeks and 12 weeks. | Change from baseline to 12 weeks | |
Secondary | Short Form 36 (SF-36) | Short Form 36 (SF-36) -ranges between 0 (maximum disability) and 100 (no disability). The SF36 score can be converted to utility scores using values within the questionnaire. The questionaire was administered at baseline, 6 weeks and 12 weeks. | Change from baseline to 12 weeks | |
Secondary | Kings' Sarcoidosis Questionnaire (KSQ) | Kings' Sarcoidosis Questionnaire (KSQ) ranges between 0 and 100 with higher numbers representing better health. The questionaire was administered at baseline, 6 weeks and 12 weeks. | Change from baseline to 12 weeks | |
Secondary | Global rating of concept scale | Global rating of concept scale. This is a ranking between 6 options to rate overall quality of life from no problem to very severe problem. The questionaire was administered at baseline, 6 weeks and 12 weeks. | Change from baseline to 12 weeks | |
Secondary | The global rating of change | The global rating of change. This is a scoring out of 15 options to rate change in quality of life. It ranges between -7 and 7 with positive values representing an improvement. The questionaire was administered at 6 weeks and 12 weeks. | Change from 6 weeks to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04008069 -
Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
|
Phase 2 | |
Recruiting |
NCT02807025 -
Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases
|
N/A | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT00274352 -
A Study of Adalimumab to Treat Sarcoidosis of the Skin
|
Phase 2 | |
Completed |
NCT00373555 -
Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis
|
N/A | |
Completed |
NCT00326534 -
Rickettsial Genesis to Sarcoidosis in Denmark
|
N/A | |
Recruiting |
NCT00470327 -
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
|
||
Completed |
NCT00512967 -
The Occurence of Inflammation and Oxidative Stress in Lung Diseases
|
N/A | |
Recruiting |
NCT01745237 -
Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
|
||
Completed |
NCT00369980 -
Diagnostic Usefulness of Fluorine–18-α–Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient
|
N/A | |
Completed |
NCT00379275 -
Eye and Immunogenetic Features of Sarcoidosis
|
N/A | |
Completed |
NCT00366509 -
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
|
||
Completed |
NCT06396910 -
TB and Sarcoidosis Granuloma
|
||
Completed |
NCT04156789 -
Obstructive Sleep Apnoea in Sarcoidosis
|
||
Recruiting |
NCT02916459 -
EBUS-TBNA vs Flex 19G EBUS-TBNA
|
N/A | |
Recruiting |
NCT02827734 -
Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
|
||
Completed |
NCT02546388 -
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
|
N/A | |
Completed |
NCT01687517 -
Efficacy and Safety of Influenza Vaccine During Sarcoidosis
|
Phase 3 | |
Completed |
NCT01139710 -
Sarcoidosis-associated Pulmonary Hypertension
|
N/A | |
Terminated |
NCT00747461 -
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
|
Phase 4 |